Sickle Cell Disease Treatment Market Size, Share, Growth Analysis, By Treatment type(Pharmaceuticals and supportive care), By End user(Hospitals, clinics, research institutes, and others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35D2091 | Region: Global | Published Date: March, 2024
Pages: 219 |Tables: 62 |Figures: 75

Sickle Cell Disease Treatment Market Insights

Global Sickle Cell Disease Treatment Market size was valued at USD 2.10 billion in 2022 and is poised to grow from USD 2.55 billion in 2023 to USD 12.03 billion by 2031, growing at a CAGR of 21.4% during the forecast period (2024-2031).

Growing incidence of sickle cell diseases around the world is projected to primarily augment the demand for sickle cell disease treatment. The prevalence of sickle cell disease is especially high in Africa, the Middle East, and India owing to limited early detection, lack of awareness, and genetic predisposition. Increasing investments in the research and development of novel treatments for rare and chronic diseases are also expected to create new opportunities for sickle cell disease treatment companies in the future. Launch of new supportive initiatives by governments and non-profit organizations to promote awareness regarding sickle cell disease treatment will also create new business scope for market players going forward. Increasing availability of novel drugs and expansion of sickle cell disease treatment drug pipelines are also slated to contribute to sickle cell disease treatment market growth in the long run. However, safety issues with novel treatments, complex regulatory landscape for genetic treatments, and lack of awareness are some major constraints that are estimated to slow down the global sickle cell disease treatment industry through 2031 and beyond. 

US Sickle Cell Disease Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 2.10 billion

Largest Segment

Pharmaceuticals

Fastest Growth

Pharmaceuticals

Growth Rate

21.4% CAGR

Global Sickle Cell Disease Treatment Market ($ Bn)
Country Share for Middle East & Africa Region (%)

To get more reports on the above market click here to Buy The Report

Sickle Cell Disease Treatment Market Segmental Analysis

Global Sickle Cell Disease Treatment Market is segmented on the basis of treatment type, end user, and region. By treatment type, the market is segmented into pharmaceuticals and supportive care. By end user, the market is segmented into hospitals, clinics, research institutes, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Analysis by Treatment Type 

Blood transfusion is projected to emerge as the segment with the largest sickle cell disease treatment market share in the future. High adoption of blood transfusions and proven efficacy of the same in managing sickle cell disease has allowed this segment to lead the overall sickle cell disease treatment demand outlook. Increasing blood donations around the world and lack of availability of other treatment alternatives are also expected to further aid the dominance of this segment in the long run. Use of blood transfusion also helps in reducing complications in the overall sickle cell disease treatment.  

Meanwhile, the demand for pharmacotherapy to treat sickle cell disease is forecasted to increase at a rapid pace across the study period and beyond. Advancements in pharmaceutical technologies, growing investments in drug discovery and development, and rising emphasis on reducing complications in sickle cell disease are helping this segment generate new opportunities for sickle cell disease treatment providers in the future. Expansion of sickle cell disease treatment drug pipelines and increasing number of clinical trials to prove the efficacy of pharmacotherapy in the treatment of various diseases will offer lucrative business scope for sickle cell disease treatment companies through 2031.   

Analysis by End User 

Hospitals are forecasted to account for a major chunk of the global sickle cell disease treatment market outlook in the future. The increasing number of sickle cell disease treatment procedures being performed in hospitals and the growing rate of hospitalization in sickle cell disease are expected to aid the dominance of this segment over the coming years. Growing availability of multiple novel sickle cell disease treatment therapies and procedures in hospitals is also estimated to boost revenue generation for market players focusing on this segment going forward. Availability of hematologists, genetic counselors, nurses, and other healthcare professionals in hospitals also helps the high share of this segment.  

On the other hand, the demand for sickle cell disease treatment in specialty clinics is forecasted to rise at an impressive CAGR over the coming years. Increasing use of advanced therapies and therapeutics for sickle cell disease treatment has resulted in many people approaching specialty clinics for their treatment. Rising investments in the development of multiple specialty clinics to reduce mortality rates and increase accessibility to novel treatment alternatives will also further create new business scope for sickle cell disease treatment market players in the long run. Development and adoption of advanced genetic therapies for sickle cell disease treatment will also help this segment bolster sickle cell disease treatment industry growth across the study period and beyond. 

Global Sickle Cell Disease Treatment Market By Treatment Type

To get detailed analysis on other segments, Request For Free Sample Report

Sickle Cell Disease Treatment Market Regional Insights

North America is estimated to lead the demand for sickle cell disease treatment on a global level. High investments in medical research, presence of a developed healthcare infrastructure, and high healthcare expenditure make this region a prime market for sickle cell disease treatment companies. Increasing willingness of patients in the United States to spend more on advanced treatment alternatives and growing medical tourism in the country allows it to emerge as the top market for sickle cell disease treatment companies operating in North America. Robust investments and advancements in gene therapies and technologies are also expected to help the dominance of this region in the long run.

Surging prevalence of sickle cell disease in the Asia-Pacific region coupled with growing awareness regarding the same are making it a highly opportune market for sickle cell disease treatment companies. High emphasis in healthcare infrastructure development, growing healthcare expenditure of patients in this region, and increasing availability of novel treatment alternatives are creating an opportune setting for sickle cell disease treatment providers in this region. India and Japan are slated to be the top markets for sickle cell disease treatment companies to target in the Asia Pacific region through 2031 and beyond. Efforts of governments and non-profit health organizations to increase awareness regarding sickle cell disease will also bolster sickle cell disease treatment market growth over the coming years. 

Global Sickle Cell Disease Treatment Market By Geography
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Sickle Cell Disease Treatment Market Dynamics

Drivers

Rising Incidence of Sickle Cell Disease 

  • Genetic predisposition and lack of early detection have resulted in a major hike in incidence of sickle cell disease around the world. Africa, India, and the Middle East are projected to key countries where the prevalence of sickle cell disease is high thereby making them highly opportune markets for sickle cell disease treatment providers as well. 

Advancements in Genetic Research 

  • Gene therapies and gene therapeutics have come a long way and are continually advancing owing to high investments in their R&D. These advancements have allowed researchers and doctors to understand sickle cell disease better and potentially even treat it by modifying the patient’s DNA to reduce complications and provide a long-term treatment as compared to a symptomatic one. 

Restraints 

Limited Awareness and Diagnosis 

  • People are not aware regarding the symptoms of sickle cell disease and this lack of awareness has translated into late diagnosis. Moreover, inadequate diagnostic infrastructure also resulted in multiple cases going undiagnosed or are diagnosed too late for optimal intervention thereby impeding the demand for sickle cell disease treatment going forward.  

Safety Concerns with Novel Treatments 

  • While novel sickle cell disease treatment and therapeutics offer significant promise, they also come with a long list of potential side effects and inadequate information about their long-term impact on human health. Moreover, complying with sickle cell disease treatment safety standards is also a key issue that is estimated to inhibit the adoption of novel treatments and slow down sickle cell disease treatment market growth in the future.

Request Free Customization of this report to help us to meet your business objectives.

Sickle Cell Disease Treatment Market Competitive Landscape

Sickle cell disease treatment providers should focus on investing heavily in research and development to come up with novel treatments and therapies. Sickle cell disease treatment companies can also focus on gaining approvals for their novel treatment products and therapies from regulatory bodies and governments. Collaborations and partnerships are also expected to emerge as highly popular strategies for market players looking to enhance their revenue generation potential in the future. 

Top Player’s Company Profile

  • Novartis (Switzerland)
  • Pfizer (US)
  • Global Blood Therapeutics (US)
  • Bluebird Bio (US)
  • Bristol Myers Squibb (US)
  • Sangamo Therapeutics (US)
  • Emmaus Life Sciences (US)
  • Eli Lilly and Company (US)
  • Modus Therapeutics (Sweden)
  • Gamida Cell (Israel)
  • Lonza Group (Switzerland)
  • Addmedica (France)
  • Selexys Pharmaceuticals (US)
  • GlycoMimetics (US)
  • Mast Therapeutics (US)
  • Acceleron Pharma (US)
  • Angiocrine Bioscience (US)
  • Imara Inc. (US)
  • AstraZeneca (UK)
  • Sanofi (France)

Recent Developments

  • In May 2024, the National Health Service (NHS) announced the launch of a new drug for sickle cell disease treatment Voxelotor. The treatment was previously approved by National Institute for Health and Care Excellence (NICE) as it could potentially help improve the quality of life for people affected by sickle cell disease in the United Kingdom.  
  • In March 2024, Akums Drugs and Pharmaceutical, a pharmaceutical contract manufacturing company based in India announced the launch of a new room-temperature treatment for sickle cell disease. The new oral suspension of Hydroxyurea treatment eliminates the need for cold storage and makes it more accessible to general people.  
  • In December 2023, the United States Food and Drug Administration (FDA) announced the approval of first gene-based therapies for sickle cell disease treatment. Casgevy and Lyfgenia were the two novel treatments approved by the regulatory body and made available for patients of 12 years or older. 

Sickle Cell Disease Treatment Key Market Trends

  • Collaborations to Increase Accessibility: Sickle cell disease treatment availability varies from region to region, and this has resulted in low adoption of novel treatments and therapies. Governments, non-profit organizations, and healthcare companies can team to improve accessibility and affordability of treatments for patients around the world to boost revenue generation in the long run.  
  • Personalized Medicine Approach: Sickle cell disease treatment providers can focus on adoption of the personalized medicine approach to increase the chances of successful treatment for patients. Growing investments in personalized medicine development and rising demand for personalized medicine among patients are expected to be key sickle cell disease treatment market trends that companies can target to boost revenue in the long run. 

Sickle Cell Disease Treatment Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.  

As per SkyQuest analysis, growing incidence of sickle cell disease and increasing advancements in genetic therapies and treatments are projected to drive the global sickle cell disease treatment market growth. However, limited awareness regarding sickle cell disease treatment and safety concerns for novel treatment alternatives and products are forecasted to impede sickle cell disease treatment demand outlook in the future. North America is expected to lead the global sickle cell disease treatment market outlook owing to high investments in medical R&D and the presence of key sickle cell disease treatment providers. Focusing on collaborations and personalized medicine trends will offer new business scope for sickle cell disease treatment companies in the long run. 

Report Metric Details
Market size value in 2022 USD 2.10 billion
Market size value in 2031 USD 12.03 billion
Growth Rate 21.4%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Treatment type
    • Pharmaceuticals and supportive care
  • End user
    • Hospitals, clinics, research institutes, and others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Novartis (Switzerland)
  • Pfizer (US)
  • Global Blood Therapeutics (US)
  • Bluebird Bio (US)
  • Bristol Myers Squibb (US)
  • Sangamo Therapeutics (US)
  • Emmaus Life Sciences (US)
  • Eli Lilly and Company (US)
  • Modus Therapeutics (Sweden)
  • Gamida Cell (Israel)
  • Lonza Group (Switzerland)
  • Addmedica (France)
  • Selexys Pharmaceuticals (US)
  • GlycoMimetics (US)
  • Mast Therapeutics (US)
  • Acceleron Pharma (US)
  • Angiocrine Bioscience (US)
  • Imara Inc. (US)
  • AstraZeneca (UK)
  • Sanofi (France)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Sickle Cell Disease Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Sickle Cell Disease Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Sickle Cell Disease Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Sickle Cell Disease Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Sickle Cell Disease Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Sickle Cell Disease Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Sickle Cell Disease Treatment Market size was valued at USD 2.10 billion in 2022 and is poised to grow from USD 2.55 billion in 2023 to USD 12.03 billion by 2031, growing at a CAGR of 21.4% during the forecast period (2024-2031).

Sickle cell disease treatment providers should focus on investing heavily in research and development to come up with novel treatments and therapies. Sickle cell disease treatment companies can also focus on gaining approvals for their novel treatment products and therapies from regulatory bodies and governments. Collaborations and partnerships are also expected to emerge as highly popular strategies for market players looking to enhance their revenue generation potential in the future.  'Novartis (Switzerland)', 'Pfizer (US)', 'Global Blood Therapeutics (US)', 'Bluebird Bio (US)', 'Bristol Myers Squibb (US)', 'Sangamo Therapeutics (US)', 'Emmaus Life Sciences (US)', 'Eli Lilly and Company (US)', 'Modus Therapeutics (Sweden)', 'Gamida Cell (Israel)', 'Lonza Group (Switzerland)', 'Addmedica (France)', 'Selexys Pharmaceuticals (US)', 'GlycoMimetics (US)', 'Mast Therapeutics (US)', 'Acceleron Pharma (US)', 'Angiocrine Bioscience (US)', 'Imara Inc. (US)', 'AstraZeneca (UK)', 'Sanofi (France)'

Genetic predisposition and lack of early detection have resulted in a major hike in incidence of sickle cell disease around the world. Africa, India, and the Middle East are projected to key countries where the prevalence of sickle cell disease is high thereby making them highly opportune markets for sickle cell disease treatment providers as well. 

Collaborations to Increase Accessibility: Sickle cell disease treatment availability varies from region to region, and this has resulted in low adoption of novel treatments and therapies. Governments, non-profit organizations, and healthcare companies can team to improve accessibility and affordability of treatments for patients around the world to boost revenue generation in the long run.  

North America is estimated to lead the demand for sickle cell disease treatment on a global level. High investments in medical research, presence of a developed healthcare infrastructure, and high healthcare expenditure make this region a prime market for sickle cell disease treatment companies. Increasing willingness of patients in the United States to spend more on advanced treatment alternatives and growing medical tourism in the country allows it to emerge as the top market for sickle cell disease treatment companies operating in North America. Robust investments and advancements in gene therapies and technologies are also expected to help the dominance of this region in the long run.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Report ID: SQMIG35D2091

$5,300
BUY NOW GET FREE SAMPLE